This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
earnings-growth: Archive
Is RTX (RTX) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for RTX (RTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
RTXNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Brokers Suggest Investing in Dorian LPG (LPG): Read This Before Placing a Bet
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Dorian LPG (LPG). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
LPGNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is Celestica (CLS) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Celestica (CLS). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
CLSNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Here is Why Growth Investors Should Buy Ahold (ADRNY) Now
by Zacks Equity Research
Ahold (ADRNY) could produce exceptional returns because of its solid growth attributes.
ADRNYPositive Net Change
earnings-growth growth-investing growth-investors growth-stocks
Here is Why Growth Investors Should Buy Calix (CALX) Now
by Zacks Equity Research
Calix (CALX) could produce exceptional returns because of its solid growth attributes.
CALXNegative Net Change
earnings-growth growth-investing growth-investors growth-stocks
3 Reasons Why Growth Investors Shouldn't Overlook Wabtec (WAB)
by Zacks Equity Research
Wabtec (WAB) could produce exceptional returns because of its solid growth attributes.
WABNegative Net Change
earnings-growth growth-investing growth-investors growth-stocks
Here is Why Growth Investors Should Buy Agnico (AEM) Now
by Zacks Equity Research
Agnico (AEM) could produce exceptional returns because of its solid growth attributes.
AEMPositive Net Change
earnings-growth growth-investing growth-investors growth-stocks
Is It Worth Investing in Snowflake (SNOW) Based on Wall Street's Bullish Views?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Snowflake (SNOW) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
SNOWNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Wall Street Analysts See Schlumberger (SLB) as a Buy: Should You Invest?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Schlumberger (SLB) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
SLBNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Wall Street Analysts See Axon (AXON) as a Buy: Should You Invest?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Axon (AXON). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
AXONNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is Microsoft (MSFT) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Microsoft (MSFT) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
MSFTNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Brokers Suggest Investing in Blue Bird (BLBD): Read This Before Placing a Bet
by Zacks Equity Research
The average brokerage recommendation (ABR) for Blue Bird (BLBD) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
BLBDNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Wall Street Analysts See Booking Holdings (BKNG) as a Buy: Should You Invest?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Booking Holdings (BKNG). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
BKNGNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Brokers Suggest Investing in Agnico (AEM): Read This Before Placing a Bet
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Agnico (AEM) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
AEMPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Duke Energy (DUK) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Duke Energy (DUK) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
DUKPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is Diebold Nixdorf, Incorporated (DBD) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Diebold Nixdorf, Incorporated (DBD) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
DBDNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Brokers Suggest Investing in Tutor Perini (TPC): Read This Before Placing a Bet
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Tutor Perini (TPC) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
TPCNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
3 Reasons Growth Investors Will Love OR Royalties (OR)
by Zacks Equity Research
OR Royalties (OR) possesses solid growth attributes, which could help it handily outperform the market.
ORPositive Net Change
earnings-growth growth-investing growth-investors growth-stocks
Is Ralph Lauren (RL) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Ralph Lauren (RL) is well positioned to outperform the market, as it exhibits above-average growth in financials.
RLNegative Net Change
earnings-growth growth-investing growth-investors growth-stocks
Here is Why Growth Investors Should Buy Aramark (ARMK) Now
by Zacks Equity Research
Aramark (ARMK) possesses solid growth attributes, which could help it handily outperform the market.
ARMKNegative Net Change
earnings-growth growth-investing growth-investors growth-stocks
Here is Why Growth Investors Should Buy Vermilion (VET) Now
by Zacks Equity Research
Vermilion (VET) is well positioned to outperform the market, as it exhibits above-average growth in financials.
VETNegative Net Change
earnings-growth growth-investing growth-investors growth-stocks
3 Reasons Why Growth Investors Shouldn't Overlook Array Technologies (ARRY)
by Zacks Equity Research
Array Technologies (ARRY) could produce exceptional returns because of its solid growth attributes.
ARRYNegative Net Change
earnings-growth growth-investing growth-investors growth-stocks
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
ADMAPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Brokers Suggest Investing in SkyWest (SKYW): Read This Before Placing a Bet
by Zacks Equity Research
The average brokerage recommendation (ABR) for SkyWest (SKYW) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
SKYWNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is It Worth Investing in SkyWater Technology (SKYT) Based on Wall Street's Bullish Views?
by Zacks Equity Research
The average brokerage recommendation (ABR) for SkyWater Technology (SKYT) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
SKYTNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth